Pharmaceutical companyEliLilly warning in an open letter on Thursday about the dangers of fake and compounded versions of its diabetes and weight loss medications Mounjaro and Zepbound.
One of the highlights of EliLilly's third-quarter results ... Lilly's head of diabetes, Mike Mason, said on the company's results call that the rollout of Mounjaro (tirzepatide) was "really ...
EliLilly (NYSE: LLY), the developer of Mounjaro, has proven that it can compete with Novo Nordisk at a high level. Moreover, the company's sibling treatment to Mounjaro -- Zepbound -- has ...
EliLillyand Company (NYSE: LLY ... evaluating the efficacy and safety of tirzepatide (Zepbound® and Mounjaro®) once weekly for long-term weight management and delay in progression to ...